Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

DelMar Pharma to Raise $8 Million in Private Placement

publication date: Jun 19, 2015
DelMar Pharma, a Vancouver-Menlo Park drug developer with significant ties to China, announced plans to raise up to $8 million in a secondary offering. Two weeks ago, the company reported positive data from an early-stage trial of VAL-083 in patients with gliobastoma multiforme. DelMar sources VAL-083 from Guangxi Wuzhou Pharma in China, where it is approved to treat leukemia and lung cancer. DelMar owns China rights to the drug for the glioblastoma multiforme indication. More details....

Stock Symbol: (OTC: DMPI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here